Although Botox and RT002 both have type-A botulinum toxin as their active ingredient, they are not therapeutic equivalents, and RT002 will never face generic competition. Hence, the FDA’s Orphan Drug Designation for RT002 in cervical dystonia has minimal practical consequence aside from saving RVNC a little money on FDA application fees.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.